Pacific Biosciences of California, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Pacific Biosciences of California, Inc. reports a strategic shift towards HiFi sequencing, an asset sale, and a net loss of $546.4 million for fiscal year 2025, alongside a decrease in cash and investments.
NASDAQ
Pacific Biosciences' 2024 results reveal a revenue decline offset by strategic initiatives and product launches, setting the stage for a transformative 2025.
NASDAQ
Pacific Biosciences' 2023 financial results show significant revenue growth due to the commercial release of its Revio and Onso sequencing platforms, though gross margins declined.